Mga Batayang Estadistika
| LEI | 549300FECER0XBN49756 |
| CIK | 914475 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Neurocrine Biosciences, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| July 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2025 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-22705 (Commission File Numb |
|
| July 30, 2025 |
Exhibit 99.1 Neurocrine Biosciences Reports Second Quarter 2025 Financial Results Achieved Total Net Product Sales of $682 Million Representing 17% Year-Over-Year Growth INGREZZA® (valbenazine) Second-Quarter 2025 Net Product Sales of $624 Million and Narrows 2025 Net Product Sales Guidance to $2.5 - $2.55 Billion CRENESSITY® (crinecerfont) Second-Quarter 2025 Net Product Sales of $53 Million with |
|
| July 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-22705 NEUROCRINE B |
|
| May 30, 2025 |
exhibit101 Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (hereinafter this “Agreement”) is entered into as of May 30, 2025 and made effective as of the Effective Date (defined in Annex I) by and between NEUROCRINE BIOSCIENCES, INC., 6027 Edgewood Bend Court, San Diego, California 92130 (hereinafter the “Company”, as further defined in Annex I |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2025 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer of |
|
| May 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2025 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer of |
|
| May 21, 2025 |
As filed with the Securities and Exchange Commission on May 21, 2025 S-8 POS As filed with the Securities and Exchange Commission on May 21, 2025 Registration No. |
|
| May 21, 2025 |
As filed with the Securities and Exchange Commission on May 21, 2025 S-8 POS As filed with the Securities and Exchange Commission on May 21, 2025 Registration No. |
|
| May 21, 2025 |
Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan, as amended and restated Exhibit 99.1 NEUROCRINE BIOSCIENCES, INC. 2018 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: FEBRUARY 6, 2018 APPROVED BY THE STOCKHOLDERS: MAY 24, 2018 AMENDED AND RESTATED BY THE COMPENSATION COMMITTEE: MARCH 14, 2022 APPROVED BY THE STOCKHOLDERS: MAY 18, 2022 AMENDED AND RESTATED BY THE COMPENSATION COMMITTEE: MARCH 14, 2025 APPROVED BY THE STOCKHOLDERS: MAY 21, 2025 1. GENERA |
|
| May 21, 2025 |
Exhibit 99.5 NEUROCRINE BIOSCIENCES, INC. 2025 EQUITY INCENTIVE PLAN OPTION GRANT NOTICE Neurocrine Biosciences, Inc. (the “Company”) has granted to you (“Participant”) an option to purchase the number of shares of Common Stock set forth below (the “Option”) under the Neurocrine Biosciences, Inc. 2025 Equity Incentive Plan (the “Plan”). The Option is subject to all of the terms and conditions set |
|
| May 21, 2025 |
As filed with the Securities and Exchange Commission on May 21, 2025 As filed with the Securities and Exchange Commission on May 21, 2025 Registration No. |
|
| May 21, 2025 |
As filed with the Securities and Exchange Commission on May 21, 2025 As filed with the Securities and Exchange Commission on May 21, 2025 Registration No. |
|
| May 21, 2025 |
Exhibit 99.7 NEUROCRINE BIOSCIENCES, INC. 2025 EQUITY INCENTIVE PLAN OPTION GRANT NOTICE – NON-U.S. Neurocrine Biosciences, Inc. (the “Company”) has granted to you (“Participant”) an option to purchase the number of shares of Common Stock set forth below (the “Option”) under the Neurocrine Biosciences, Inc. 2025 Equity Incentive Plan (the “Plan”). The Option is subject to all of the terms and cond |
|
| May 21, 2025 |
Exhibit 99.4 NEUROCRINE BIOSCIENCES, INC. 2025 EQUITY INCENTIVE PLAN RSU AWARD GRANT NOTICE Neurocrine Biosciences, Inc. (the “Company”) has granted to you (“Participant”) a restricted stock unit award for the number of restricted stock units (“RSUs”) set forth below (the “RSU Award”) under the Neurocrine Biosciences, Inc. 2025 Equity Incentive Plan (the “Plan”). The RSU Award is subject to all of |
|
| May 21, 2025 |
As filed with the Securities and Exchange Commission on May 21, 2025 S-8 POS As filed with the Securities and Exchange Commission on May 21, 2025 Registration No. |
|
| May 21, 2025 |
Calculation of Filing Fee Tables S-8 NEUROCRINE BIOSCIENCES INC Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common stock, $0. |
|
| May 21, 2025 |
As filed with the Securities and Exchange Commission on May 21, 2025 S-8 POS As filed with the Securities and Exchange Commission on May 21, 2025 Registration No. |
|
| May 21, 2025 |
As filed with the Securities and Exchange Commission on May 21, 2025 As filed with the Securities and Exchange Commission on May 21, 2025 Registration No. |
|
| May 21, 2025 |
As filed with the Securities and Exchange Commission on May 21, 2025 As filed with the Securities and Exchange Commission on May 21, 2025 Registration No. |
|
| May 21, 2025 |
As filed with the Securities and Exchange Commission on May 21, 2025 S-8 POS As filed with the Securities and Exchange Commission on May 21, 2025 Registration No. |
|
| May 21, 2025 |
Exhibit 99.8 NEUROCRINE BIOSCIENCES, INC. 2025 EQUITY INCENTIVE PLAN RSU AWARD GRANT NOTICE – NON-U.S. Neurocrine Biosciences, Inc. (the “Company”) has granted to you (“Participant”) a restricted stock unit award for the number of restricted stock units (“RSUs”) set forth below (the “RSU Award”) under the Neurocrine Biosciences, Inc. 2025 Equity Incentive Plan (the “Plan”). The RSU Award is subjec |
|
| May 21, 2025 |
Exhibit 99.6 NEUROCRINE BIOSCIENCES, INC. 2025 EQUITY INCENTIVE PLAN RSU AWARD GRANT NOTICE Neurocrine Biosciences, Inc. (the “Company”) has granted to you (“Participant”) a restricted stock unit award for the number of restricted stock units (“RSUs”) set forth below (the “RSU Award”) under the Neurocrine Biosciences, Inc. 2025 Equity Incentive Plan (the “Plan”). The RSU Award is subject to all of |
|
| May 21, 2025 |
Exhibit 99.3 NEUROCRINE BIOSCIENCES, INC. 2025 EQUITY INCENTIVE PLAN OPTION GRANT NOTICE Neurocrine Biosciences, Inc. (the “Company”) has granted to you (“Participant”) an option to purchase the number of shares of Common Stock set forth below (the “Option”) under the Neurocrine Biosciences, Inc. 2025 Equity Incentive Plan (the “Plan”). The Option is subject to all of the terms and conditions set |
|
| May 21, 2025 |
Neurocrine Biosciences, Inc. 2025 Equity Incentive Plan Exhibit 99.2 NEUROCRINE BIOSCIENCES, INC. 2025 EQUITY INCENTIVE PLAN ADOPTED BY THE COMPENSATION COMMITTEE: MARCH 14, 2025 APPROVED BY THE STOCKHOLDERS: MAY 21, 2025 1. GENERAL. (a) Relationship to Prior Plans. The Plan is the successor to the 2020 Plan. As of the Effective Date: (i) no additional awards may be granted under the 2020 Plan; and (ii) all Prior Plan Awards will remain subject to the |
|
| May 21, 2025 |
As filed with the Securities and Exchange Commission on May 21, 2025 S-8 POS As filed with the Securities and Exchange Commission on May 21, 2025 Registration No. |
|
| May 21, 2025 |
As filed with the Securities and Exchange Commission on May 21, 2025 As filed with the Securities and Exchange Commission on May 21, 2025 Registration No. |
|
| May 21, 2025 |
As filed with the Securities and Exchange Commission on May 21, 2025 S-8 POS As filed with the Securities and Exchange Commission on May 21, 2025 Registration No. |
|
| May 21, 2025 |
As filed with the Securities and Exchange Commission on May 21, 2025 As filed with the Securities and Exchange Commission on May 21, 2025 Registration No. |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-22705 (Commission File Number |
|
| May 5, 2025 |
Form of Stock Option Grant Notice and Option Agreement for grants made Exhibit 10.1 NEUROCRINE BIOSCIENCES, INC. 2020 EQUITY INCENTIVE PLAN OPTION GRANT NOTICE Neurocrine Biosciences, Inc. (the “Company”) has granted to you (“Participant”) an option to purchase the number of shares of Common Stock set forth below (the “Option”) under the Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan (the “Plan”). The Option is subject to all of the terms and conditions set |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-22705 NEUROCRINE |
|
| May 5, 2025 |
between Takeda Pharmaceutical Company Limited and the Company Exhibit 10.8 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Triple asterisks denote omissions. CONFIDENTIAL Execution Version AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT BY AND BETWEEN TAKEDA PHARMACEUTICAL COMPANY LIMITED AND NEUROCRINE BIOSCIENCES |
|
| May 5, 2025 |
Exhibit 99.1 Neurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance INGREZZA® (valbenazine) First-Quarter 2025 Net Product Sales of $545 Million and Reaffirms 2025 Net Product Sales Guidance of $2.5 - $2.6 Billion CRENESSITYTM (crinecerfont) First-Quarter 2025 Net Product Sales of $14.5 Million with 413 Total Patient Enrollment Start Forms Initiat |
|
| April 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2025 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer of |
|
| April 4, 2025 |
Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer Exhibit 99.1 Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer • Accomplished physician-scientist brings more than 20 years of industry leadership experience and broad R&D expertise in multiple therapeutic areas SAN DIEGO, April 4, 2025 - Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Sanjay Keswani, M.D., to the company’s executive managem |
|
| February 10, 2025 |
Amended and Restated Employment Agreement effective exhibit1031-kyleganoxame Exhibit 10.31 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (hereinafter this “Agreement”) is entered into effective February 7, 2025 (hereinafter the “Effective Date”) by and between NEUROCRINE BIOSCIENCES, INC., 6027 Edgewood Bend Court, San Diego, California 92130 (hereinafter the “Company”, as further defined in Annex I), and |
|
| February 10, 2025 |
Amended and Restated Employment Agreement effective February Exhibit 10.32 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (hereinafter this “Agreement”) is entered into effective February 7, 2025 (hereinafter the “Effective Date”) by and between NEUROCRINE BIOSCIENCES, INC., 6027 Edgewood Bend Court, San Diego, California 92130 (hereinafter the “Company”, as further defined in Annex I), and Matthew Abernethy (herein |
|
| February 10, 2025 |
exhibit1026-executivesev Exhibit 10.26 1 NEUROCRINE BIOSCIENCES, INC. EXECUTIVE SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION (Effective Date: February 7, 2025) 1. Introduction. The Neurocrine Biosciences, Inc. Executive Severance Plan (the “Plan”) is hereby established by the Compensation Committee (as defined below), effective upon the Effective Date written above. The purpose of the Plan is to pr |
|
| February 10, 2025 |
Exhibit 21.1 NEUROCRINE BIOSCIENCES INC. SUBSIDIARIES Name of Subsidiary Jurisdiction Neurocrine Continental, Inc. Delaware, USA Neurocrine International, Inc. Delaware, USA Neurocrine Group Limited England and Wales Neurocrine UK Limited England and Wales Neurocrine Holdings Limited England and Wales Neurocrine Ireland Limited Ireland Neurocrine Therapeutics Limited Ireland Neurocrine Switzerland |
|
| February 10, 2025 |
Neurocrine Biosciences, Inc. Insider Trading Policy exhibit191insidertrading Exhibit 19.1 NEUROCRINE BIOSCIENCES, INC. INSIDER TRADING POLICY INTRODUCTION During the course of your relationship with Neurocrine Biosciences, Inc. (the “Company”), you may receive material information that is not yet publicly available (“material nonpublic information”) about the Company or another publicly-traded company with which the Company has business dealings. M |
|
| February 10, 2025 |
Exhibit 10.4 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Triple asterisks denote omissions. COLLABORATION AND LICENSE AGREEMENT By and between VOYAGER THERAPEUTICS, INC. AND NEUROCRINE BIOSCIENCES, INC. i TABLE OF CONTENTS ARTICLE 1 DEFINITIONS ...... |
|
| February 10, 2025 |
Amended and Restated Employment Agreement effective February exhibit1033-ericbenevich Exhibit 10.33 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (hereinafter this “Agreement”) is entered into effective February 7, 2025 (hereinafter the “Effective Date”) by and between NEUROCRINE BIOSCIENCES, INC., 6027 Edgewood Bend Court, San Diego, California 92130 (hereinafter the “Company”, as further defined in Annex I), and |
|
| February 10, 2025 |
exhibit1030-kyleganoxemp Exhibit 10.30 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (hereinafter this “Agreement”) is entered into effective October 11, 2024 (hereinafter the “Effective Date”) by and between NEUROCRINE BIOSCIENCES, INC., 6027 Edgewood Bend Court, San Diego, California 92130 (hereinafter the “Company”, as further defined in Annex I), and |
|
| February 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-22705 NEUROCRINE BIOSCIENCES, INC. (E |
|
| February 10, 2025 |
Amended and Restated Employment Agreement effective February 307632958 v9 Exhibit 10.35 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (hereinafter this “Agreement”) is entered into effective February 7, 2025 (hereinafter the “Effective Date”) by and between NEUROCRINE BIOSCIENCES, INC., 6027 Edgewood Bend Court, San Diego, California 92130 (hereinafter the “Company”, as further defined in Annex I), and Eiry W. Robe |
|
| February 10, 2025 |
Amended and Restated Employment Agreement effective Februar exhibit1034-judeonyiaxam Exhibit 10.34 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (hereinafter this “Agreement”) is entered into effective February 7, 2025 (hereinafter the “Effective Date”) by and between NEUROCRINE BIOSCIENCES, INC., 6027 Edgewood Bend Court, San Diego, California 92130 (hereinafter the “Company”, as further defined in Annex I), and |
|
| February 6, 2025 |
Exhibit 99.1 Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2024 Financial Results and Provides Financial Expectations for 2025 INGREZZA® (valbenazine) Fourth Quarter and Full Year 2024 Net Product Sales of $615 Million and $2.3 Billion, Representing Year-Over-Year Growth of 23% and 26% Respectively INGREZZA® (valbenazine) Full Year 2025 Net Product Sales Guidance of $2.5 - $2.6 Billion |
|
| February 6, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2025 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-22705 (Commission File N |
|
| January 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2025 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer |
|
| January 27, 2025 |
Exhibit 99.1 Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653) - Neurocrine Obtains Exclusive Worldwide Development and Commercialization Rights Excluding Japan and Converts to Royalty-Bearing License for Osavampator - Takeda Reacquires Rights to Osavampator in Japan SAN DIEGO, Jan. 27, 2025 – N |
|
| December 20, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2024 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employe |
|
| December 20, 2024 |
Exhibit 99.1 Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia • CRENESSITY, a First-in-Class Treatment for Classic Congenital Adrenal Hyperplasia (CAH), is now commercially available in the U.S. • CAH-trained pharmacists are available 24/7 to support patients with prescriptions exclusively thr |
|
| November 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2024 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer |
|
| October 30, 2024 |
Neurocrine Biosciences, Inc. 2011 Equity Incentive Plan, as amended 110132325 v9 1. NEUROCRINE BIOSCIENCES, INC. 2011 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: FEBRUARY 21, 2011 APPROVED BY THE STOCKHOLDERS: MAY 25, 2011 AMENDED BY THE STOCKHOLDERS: MAY 23, 2013 AMENDED BY THE STOCKHOLDERS: MAY 22, 2014 AMENDED BY THE STOCKHOLDERS: MAY 28, 2015 AMENDED BY THE STOCKHOLDERS: MAY 20, 2016 AMENDED BY THE STOCKHOLDERS: MAY 22, 2017 AMENDED BY THE STOCKHO |
|
| October 30, 2024 |
BYLAWS OF NEUROCRINE BIOSCIENCES, INC. (a Delaware corporation) Exhibit 3.2 BYLAWS OF NEUROCRINE BIOSCIENCES, INC. (a Delaware corporation) TABLE OF CONTENTS Page - i - ARTICLE I CORPORATE OFFICES .................................................................................. 1 1.1 REGISTERED OFFICE ................................................................................................ |
|
| October 30, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2024 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-22705 (Commission File N |
|
| October 30, 2024 |
Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan, as amended 307473618 v2 NEUROCRINE BIOSCIENCES, INC. 2020 EQUITY INCENTIVE PLAN ADOPTED BY THE COMPENSATION COMMITTEE: MARCH 16, 2020 APPROVED BY THE STOCKHOLDERS: MAY 19, 2020 AMENDED AND RESTATED BY THE COMPENSATION COMMITTEE: MARCH 14, 2022 APPROVED BY THE STOCKHOLDERS: MAY 18, 2022 AMENDED AND RESTATED BY THE COMPENSATION COMMITTEE: MARCH 24, 2023 APPROVED BY THE STOCKHOLDERS: MAY 17, 2023 AMENDED AND RE |
|
| October 30, 2024 |
307480254 v2 Exhibit 10.3 NEUROCRINE BIOSCIENCES, INC. STOCK OPTION GRANT NOTICE (2011 EQUITY INCENTIVE PLAN) NEUROCRINE BIOSCIENCES, INC. (the “Company”), pursuant to its 2011 Equity Incentive Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions as set fo |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-22705 NEUROCR |
|
| October 30, 2024 |
Exhibit 99.1 Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance INGREZZA® (valbenazine) Third Quarter Net Product Sales of $613 Million Representing 26% Year-Over-Year Growth INGREZZA® (valbenazine) 2024 Net Product Sales Guidance Raised to $2.30 - $2.32 Billion Board Authorizes $300 Million Share Repurchase Plan SAN DIEGO, October 30, 2024 |
|
| October 17, 2024 |
NBIX / Neurocrine Biosciences, Inc. / STATE STREET CORP Passive Investment SC 13G 1 NeurocrineBiosciencesInc.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NEUROCRINE BIOSCIENCES INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 64125C109 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the |
|
| October 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2024 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer |
|
| August 28, 2024 |
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia Exhibit 99.1 Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia •The Once-Daily 20 mg Dose Met the Primary Endpoint, Demonstrating a Statistically Significant 7.5-Point Improvement (p=0.011, 0.61 Effect Size) in the PANSS Total Score Compared to Placebo at Week 6 with an 18.2-Point PANSS Total Score Improvement from Baseline •The Once-Daily 20 mg Dose |
|
| August 28, 2024 |
nbix2024828-exhibit992 Topline Results for Phase 2 Trial of NBI-1117568 (NBI-’568) in Schizophrenia August 28, 2024 Exhibit 99. |
|
| August 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2024 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer |
|
| August 1, 2024 |
Exhibit 99.1 Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance INGREZZA® (valbenazine) Second Quarter Net Product Sales of $580 Million Representing 32% Year-Over-Year Growth INGREZZA® (valbenazine) 2024 Net Product Sales Guidance Raised to $2.25 - $2.3 Billion Top-Line Phase 2 Data Readouts for NBI-’568 and Luvadaxistat Remain On Track in |
|
| August 1, 2024 |
Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan, as amended and restated NEUROCRINE BIOSCIENCES, INC. 2020 EQUITY INCENTIVE PLAN ADOPTED BY THE COMPENSATION COMMITTEE: MARCH 16, 2020 APPROVED BY THE STOCKHOLDERS: MAY 19, 2020 AMENDED AND RESTATED BY THE COMPENSATION COMMITTEE: MARCH 14, 2022 APPROVED BY THE STOCKHOLDERS: MAY 18, 2022 AMENDED AND RESTATED BY THE COMPENSATION COMMITTEE: MARCH 24, 2023 APPROVED BY THE STOCKHOLDERS: MAY 17, 2023 AMENDED AND RESTATED BY THE |
|
| August 1, 2024 |
, between the Company and Voyager Therapeutics, Inc. Exhibit 10.2 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. FIRST AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT This FIRST AMENDMENT TO THE COLLABORATION AND LICENSE AGREEMENT (this “Amendment”) is effective as of Ap |
|
| August 1, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-22705 (Commission File Num |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-22705 NEUROCRINE B |
|
| August 1, 2024 |
As filed with the Securities and Exchange Commission on August 1, 2024 As filed with the Securities and Exchange Commission on August 1, 2024 Registration No. |
|
| August 1, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 Neurocrine Biosciences, Inc. Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid Equity Common stock, $0.001 par value per share, 2020 Equity Incentive Plan O |
|
| May 28, 2024 |
Certificate of Amendment of Bylaws Exhibit 3.1 BYLAW AMENDMENT 3.2 NUMBER OF DIRECTORS The board of directors shall consist of eleven (11) members. The number of directors may be changed by an amendment to this bylaw, duly adopted by the board of directors or by the stockholders, or by a duly adopted amendment to the certificate of incorporation. The directors shall be divided into three classes, with the term of office of the firs |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2024 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-22705 (Commission File Numbe |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2024 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer of |
|
| May 1, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2024 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-22705 (Commission File Number |
|
| May 1, 2024 |
Exhibit 10.1 Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan RSU Award Grant Notice Neurocrine Biosciences, Inc. (the “Company”) has granted to you (“Participant”) a restricted stock unit award for the number of restricted stock units (“RSUs”) set forth below (the “RSU Award”) under the Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan (the “Plan”). The RSU Award is subject to all of |
|
| May 1, 2024 |
Neurocrine Biosciences Reports First Quarter 2024 Financial Results Exhibit 99.1 Neurocrine Biosciences Reports First Quarter 2024 Financial Results INGREZZA® (valbenazine) First Quarter Net Product Sales of $506 Million Representing 23% Year-Over-Year Growth INGREZZA® SPRINKLE (valbenazine) Capsules Approved by the U.S. FDA Crinecerfont New Drug Applications for the Treatment of Congenital Adrenal Hyperplasia Submitted to the U.S. FDA Positive Phase 2 Top-Line Da |
|
| May 1, 2024 |
Exhibit 10.2 Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan Option Grant Notice Neurocrine Biosciences, Inc. (the “Company”) has granted to you (“Participant”) an option to purchase the number of shares of Common Stock set forth below (the “Option”) under the Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan (the “Plan”). The Option is subject to all of the terms and conditions set |
|
| May 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-22705 NEUROCRINE |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| February 13, 2024 |
NBIX / Neurocrine Biosciences, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01535-neurocrinebioscience.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Neurocrine Biosciences Inc Title of Class of Securities: Common Stock CUSIP Number: 64125C109 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box |
|
| February 9, 2024 |
Exhibit 97 Neurocrine Biosciences, Inc. Incentive Compensation Recoupment Policy October 2023 1.Introduction The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Neurocrine Biosciences, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation |
|
| February 9, 2024 |
Exhibit 21.1 NEUROCRINE BIOSCIENCES INC. SUBSIDIARIES Name of Subsidiary Jurisdiction Neurocrine Continental, Inc. Delaware, USA Neurocrine International, Inc. Delaware, USA Neurocrine Europe, Ltd. Ireland Neurocrine Therapeutics, Ltd. Ireland Neurocrine UK Limited England and Wales Neurocrine Switzerland GmbH Switzerland Diurnal Group Limited England and Wales Diurnal Limited England and Wales Di |
|
| February 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-22705 NEUROCRINE BIOSCIENCES, INC. (E |
|
| February 7, 2024 |
Exhibit 99.1 Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024 INGREZZA® (valbenazine) Fourth Quarter and Full Year 2023 Net Product Sales of $500 Million and $1.84 Billion, Representing Year-over-Year Growth of 25% and 29% Respectively INGREZZA® (valbenazine) Full Year 2024 Net Product Sales Guidance of $2.1 - $2.2 Billion |
|
| February 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2024 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-22705 (Commission File N |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2023 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employe |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer |
|
| October 31, 2023 |
Exhibit 99.1 Neurocrine Biosciences Reports Third Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance INGREZZA® (valbenazine) Third Quarter Net Product Sales of $486 Million Representing 29% Year-Over-Year Growth INGREZZA® (valbenazine) 2023 Net Product Sales Guidance Raised to $1.82 - $1.84 Billion Crinecerfont Adult and Pediatric CAHtalystTM Studies Met Primary Endpoint and Ke |
|
| October 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-22705 NEUROCR |
|
| October 31, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2023 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-22705 (Commission File N |
|
| October 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2023 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer |
|
| October 5, 2023 |
Exhibit 99.1 Neurocrine Biosciences Announces Phase 3 Pediatric Study Results of Crinecerfont in Children and Adolescents for the Treatment of Congenital Adrenal Hyperplasia Met Primary and Key Secondary Endpoints •CAHtalyst™ Pediatric Study Met Primary Endpoint Demonstrating a Statistically Significant Decrease from Baseline in Serum Androstenedione in Children and Adolescents with Congenital Adr |
|
| October 5, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2023 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer |
|
| September 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2023 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employ |
|
| September 12, 2023 |
Exhibit 99.1 Neurocrine Biosciences Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH) CAHtalyst™ Met Primary Endpoint Demonstrating a Statistically Significant Decrease from Baseline Daily Glucocorticoid Dose with Androgen Control Key Secondary Endpoint Achieved Statistically Significant Decrease in Androstenedio |
|
| August 1, 2023 |
Exhibit 99.1 Neurocrine Biosciences Reports Second Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance INGREZZA® (valbenazine) Second Quarter Net Product Sales of $440 Million Representing 26% Year-Over-Year Growth INGREZZA® (valbenazine) 2023 Net Product Sales Guidance Raised to $1.77 - $1.82 Billion SAN DIEGO, Aug. 1, 2023 - Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today an |
|
| August 1, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2023 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-22705 (Commission File Num |
|
| August 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-22705 NEUROCRINE B |
|
| August 1, 2023 |
Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan, as amended and restated Exhibit 10.1 NEUROCRINE BIOSCIENCES, INC. 2020 EQUITY INCENTIVE PLAN ADOPTED BY THE COMPENSATION COMMITTEE: MARCH 16, 2020 APPROVED BY THE STOCKHOLDERS: MAY 19, 2020 AMENDED AND RESTATED BY THE COMPENSATION COMMITTEE: MARCH 14, 2022 APPROVED BY THE STOCKHOLDERS: MAY 18, 2022 AMENDED BY THE COMPENSATION COMMITTEE: MARCH 24, 2023 APPROVED BY THE STOCKHOLDERS: May 17, 2023 TERMINATION DATE: MARCH 15, |
|
| August 1, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 Neurocrine Biosciences, Inc. Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid Equity Common stock, $0.001 par value per share, 2020 Equity Incentive Plan O |
|
| August 1, 2023 |
q2-2023xexhibit32 Exhibit 3.2 BYLAWS OF NEUROCRINE BIOSCIENCES, INC. (a Delaware corporation) BYLAWS OF NEUROCRINE BIOSCIENCES, INC. (a Delaware corporation) TABLE OF CONTENTS Page - i - ARTICLE I CORPORATE OFFICES .................................................................................. 1 1.1 REGISTERED OFFICE .............................................................................. |
|
| August 1, 2023 |
As filed with the Securities and Exchange Commission on August 1, 2023 As filed with the Securities and Exchange Commission on August 1, 2023 Registration No. |
|
| July 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2023 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer of |
|
| July 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2023 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer of |
|
| July 12, 2023 |
Certificate of Amendment of Bylaws Exhibit 3.1 BYLAW AMENDMENT 3.2 NUMBER OF DIRECTORS The board of directors shall consist of ten (10) members. The number of directors may be changed by an amendment to this bylaw, duly adopted by the board of directors or by the stockholders, or by a duly adopted amendment to the certificate of incorporation. The directors shall be divided into three classes, with the term of office of the first c |
|
| May 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2023 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 3, 2023 |
q1-2023x10qxexhibit104 Exhibit 10.4 EXECUTION VERSION ACTIVEUS 197306930v.16 AMENDED AND RESTATED INVESTOR AGREEMENT By and Between NEUROCRINE BIOSCIENCES, INC. AND VOYAGER THERAPEUTICS, INC. Dated as of January 8, 2023 - i - ACTIVEUS 197306930v.16 TABLE OF CONTENTS 1. Definitions....................................................................................................................... |
|
| May 3, 2023 |
Neurocrine Biosciences Reports First Quarter 2023 Financial Results Exhibit 99.1 Neurocrine Biosciences Reports First Quarter 2023 Financial Results INGREZZA® (valbenazine) First Quarter Net Product Sales of $410 Million INGREZZA® (valbenazine) 2023 Net Product Sales Guidance Reiterated at $1.67 - $1.77 Billion SAN DIEGO, May 3, 2023 - Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2023 and p |
|
| May 3, 2023 |
Stock Purchase Agreement dated January 8, 2023 between Voyager Therapeutics, Inc. and the Company q1-2023x10qxexhibit103 Exhibit 10.3 EXECUTION VERSION ACTIVEUS 197300656v.12 STOCK PURCHASE AGREEMENT By and Between NEUROCRINE BIOSCIENCES, INC. AND VOYAGER THERAPEUTICS, INC. Dated as of January 8, 2023 ACTIVEUS 197300656v.12 TABLE OF CONTENTS Page 1. Definitions............................................................................................................................1 1.1 Defin |
|
| May 3, 2023 |
Employment Agreement dated October 28, 2014 between the Company and Darin Lippoldt q1-2023x10qxexhibit101 Exhibit 10.1 threatened breach of any such provisions by Executive, in addition to any other relief (including damage) available to the Company under this Agreement or under law. (b) Exclusive. Both parties agree that the remedy specified in Section 7.9(a) above is not exclusive of any other remedy for the breach by Executive of the tenns hereof. 7.10 Counterparts. This Agre |
|
| May 3, 2023 |
q1-2023x10qxexhibit102 Exhibit 10.2 EXECUTION COPY CONFIDENTIAL Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. 1 COLLABORATION AND LICENSE AGREEMENT by and between VOYAGER THERAPEUTICS, INC. AND NEUROCRINE BIOSCIENCES, |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-22705 NEUROCRINE |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-22705 (Commission File Number |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2023 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer o |
|
| February 24, 2023 |
EX-99.1 Exhibit 99.1 AMENDED AND RESTATED INVESTOR AGREEMENT By and Between NEUROCRINE BIOSCIENCES, INC. AND VOYAGER THERAPEUTICS, INC. Dated as of January 8, 2023 TABLE OF CONTENTS 1. Definitions 1 2. Restrictions on Beneficial Ownership 6 3. Restrictions on Dispositions 7 3.1 Lock-Up 7 3.2 Certain Tender Offers 7 3.3 Sale Limitations 7 3.4 Offering Lock-Up 8 3.5 Transactions for |
|
| February 24, 2023 |
VYGR / Voyager Therapeutics Inc / Neurocrine Biosciences Inc - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* VOYAGER THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 92915B106 (CUSIP Number) Kevin C. Gorman, Ph.D. Chief Executive Officer Neurocrine Biosciences, Inc. 12780 El Camino Real San Die |
|
| February 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employe |
|
| February 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2023 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employe |
|
| February 10, 2023 |
Exhibit 3.1 BYLAWS OF NEUROCRINE BIOSCIENCES, INC. (a Delaware corporation) BYLAWS OF NEUROCRINE BIOSCIENCES, INC. (a Delaware corporation) TABLE OF CONTENTS Page - i - ARTICLE I CORPORATE OFFICES .................................................................................. 1 1.1 REGISTERED OFFICE ................................................................................................ |
|
| February 9, 2023 |
NBIX / Neurocrine Biosciences, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01504-neurocrinebioscience.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Neurocrine Biosciences Inc. Title of Class of Securities: Common Stock CUSIP Number: 64125C109 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate bo |
|
| February 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-22705 NEUROCRINE BIOSCIENCES, INC. (E |
|
| February 9, 2023 |
Exhibit 21.1 NEUROCRINE BIOSCIENCES INC. SUBSIDIARIES Name of Subsidiary Jurisdiction Neurocrine Continental, Inc. Delaware, USA Neurocrine Europe, Ltd. Ireland Neurocrine Therapeutics, Ltd. Ireland Neurocrine UK Limited England and Wales Diurnal Group Limited England and Wales Diurnal Limited England and Wales Diurnal Europe B.V. The Netherlands |
|
| February 6, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2023 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-22705 (Commission File N |
|
| February 6, 2023 |
Exhibit 99.1 Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides Financial Expectations for 2023 INGREZZA® (valbenazine) Fourth Quarter Net Product Sales of $399 Million INGREZZA® (valbenazine) 2023 Net Product Sales Guidance of $1.67 - $1.77 Billion Enrollment Complete in Adult and Pediatric Registrational Studies of Crinecerfont for the Treatment of Conge |
|
| January 9, 2023 |
Exhibit 99.1 Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Development and Commercialization of Voyager’s GBA1 Program and Other Next-Generation Gene Therapies for Neurological Diseases - Voyager to receive up-front consideration of $175 million including a $39 million equity investment, up to $1.5 billion in potential development milestones, additional potentia |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2023 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer |
|
| November 1, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2022 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-22705 (Commission File N |
|
| November 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-22705 NEUROCR |
|
| November 1, 2022 |
Exhibit 99.1 Neurocrine Biosciences Reports Third Quarter 2022 Financial Results and Raises 2022 INGREZZA Sales Guidance INGREZZA? (valbenazine) Third Quarter Net Product Sales of $376 Million INGREZZA? (valbenazine) 2022 Net Product Sales Guidance Raised to $1.4 - $1.425 Billion Supplemental New Drug Application (sNDA) of Valbenazine For the Treatment of Chorea in Patients with Huntington Disease |
|
| August 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2022 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer |
|
| August 4, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 Neurocrine Biosciences, Inc. Table 1 ? Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid Equity Common stock, $0.001 par value per share, 2020 Equity Incentive Plan O |
|
| August 4, 2022 |
As filed with the Securities and Exchange Commission on August 4, 2022 As filed with the Securities and Exchange Commission on August 4, 2022 Registration No. |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-22705 NEUROCRINE B |
|
| August 4, 2022 |
Employment Agreement dated November 29, 2021 between the Company and Jude Onyia Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (hereinafter ?Agreement?) is entered into effective November 29, 2021 by and between Neurocrine Biosciences, Inc., 12780 El Camino Real, San Diego, California 92130 (hereinafter the ?Company?), and Jude Onyia, Ph.D. (hereinafter ?Executive?). R E C I T A L S WHEREAS, the Company and Executive wish to set forth in this Agreement the terms |
|
| August 4, 2022 |
Exhibit 99.1 Neurocrine Biosciences Reports Second Quarter 2022 Financial Results and Raises 2022 INGREZZA Sales Guidance INGREZZA? (valbenazine) Second Quarter Net Product Sales of $350 Million INGREZZA? (valbenazine) 2022 Net Product Sales Guidance Raised to $1.35 - $1.40 Billion Essential Tremor Signal-Seeking Study Did Not Meet Specified Endpoints SAN DIEGO, Aug. 4, 2022 - Neurocrine Bioscienc |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-22705 (Commission File Num |
|
| August 4, 2022 |
Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan, as amended and restated Exhibit 10.3 Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan Adopted by the Board of Directors: February 6, 2018 Approved by the Stockholders: May 24, 2018 Amended and Restated by the Compensation Committee: March 14, 2022 Approved by the Stockholders: May 18, 2022 1.General; Purpose. (a)The Plan provides a means by which Eligible Employees of the Company and certain designated Rela |
|
| August 4, 2022 |
Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan, as amended Exhibit 10.2 Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan Adopted by the Compensation Committee: March 16, 2020 Approved by the Stockholders: May 19, 2020 Amended and Restated by the Compensation Committee: March 14, 2022 Approved by the Stockholders: May 18, 2022 Termination Date: March 15, 2030 Table of Contents Page 1. General. 1 2. Shares Subject to the Plan. 1 3. Eligibility and Li |
|
| June 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2022 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer of |
|
| May 25, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2022 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer of |
|
| May 25, 2022 |
Neurocrine Biosciences Announces Repurchase of Convertible Notes Exhibit 99.1 Neurocrine Biosciences Announces Repurchase of Convertible Notes SAN DIEGO, May 24, 2022 - Neurocrine Biosciences, Inc. (Nasdaq: NBIX) (the ?Company? or ?Neurocrine Biosciences?) today announced that it has entered into separate, privately negotiated transactions (the ?Agreements?) with certain holders of its existing 2.25% Convertible Senior Notes due 2024 (the ?2024 Notes?) to repur |
|
| May 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2022 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer of |
|
| May 4, 2022 |
COMMERCIAL LEASE By and Between Gemdale Aperture Phase I, LLC a Delaware limited liability company ?Landlord? and Neurocrine Biosciences, Inc. |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-22705 NEUROCRINE |
|
| May 4, 2022 |
Exhibit 99.1 Neurocrine Biosciences Reports First Quarter 2022 Financial Results and Reiterates 2022 Financial Guidance INGREZZA? (valbenazine) First Quarter Net Product Sales of $303 Million INGREZZA? (valbenazine) 2022 Net Product Sales Guidance Reiterated at $1.25 - $1.35 Billion SAN DIEGO, May 4, 2022 - Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the f |
|
| May 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-22705 (Commission File Number |
|
| April 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 7, 2022 |
DEFA14A 1 d332755ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commissi |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-22705 NEUROCRINE BIOSCIENCES, INC. (E |
|
| February 11, 2022 |
Exhibit 10.17 Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan Option Grant Notice Neurocrine Biosciences, Inc. (the ?Company?) has granted to you (?Participant?) an option to purchase the number of shares of Common Stock set forth below (the ?Option?) under the Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan (the ?Plan?). The Option is subject to all of the terms and conditions set |
|
| February 11, 2022 |
Exhibit 21.1 NEUROCRINE BIOSCIENCES INC. SUBSIDIARIES Name of Subsidiary Jurisdiction Neurocrine Continental, Inc. Delaware, USA Neurocrine Europe, Ltd. Ireland Neurocrine Therapeutics, Ltd. Ireland |
|
| February 11, 2022 |
Exhibit 4.3 NEUROCRINE BIOSCIENCES, INC. AND U.S. BANK NATIONAL ASSOCIATION, as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of December 20, 2021 2.25% Convertible Senior Notes due 2024 FIRST SUPPLEMENTAL INDENTURE, dated as of December 20, 2021 (this ?Supplemental Indenture?), among Neurocrine Biosciences, Inc., a Delaware corporation (the ?Company?), as issuer, and U.S. Bank National Associatio |
|
| February 11, 2022 |
Exhibit 99.1 Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2021 Financial Results and Provides Financial Expectations for Fiscal 2022 INGREZZA? (valbenazine) 2021 Net Product Sales of $1.1 Billion with 200,000 TRx INGREZZA? (valbenazine) 2022 Net Product Sales Guidance of $1.25 - $1.35 Billion Expanded Pipeline Expected to Deliver Multiple Registrational and Phase 2 Study Data Readouts |
|
| February 11, 2022 |
Exhibit 10.10 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT NEUROCRINE BIOSCIENCES, INC. TREATS AS PRIVATE OR CONFIDENTIAL Dated 22 November 2021 HEPTARES THERAPEUTICS LIMITED (1) AND NEUROCRINE BIOSCIENCES, INC. (2) COLLABORATION AND LICENSE AGREEMENT CONTENTS Clause Heading Page 1 DEFIN |
|
| February 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2022 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employe |
|
| February 10, 2022 |
NBIX / Neurocrine Biosciences, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Neurocrine Biosciences Inc. Title of Class of Securities: Common Stock CUSIP Number: 64125C109 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| January 6, 2022 |
Exhibit 99.1 Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2021 Net Product Sales Results and Future Program Milestones INGREZZA? (valbenazine) Preliminary Fourth Quarter Net Product Sales of Approximately $301 Million and 56,400 Total Prescriptions INGREZZA? (valbenazine) Preliminary Full-Year 2021 Net Product Sales of Approximately $1.1 Billion Supplemental New Drug Ap |
|
| January 6, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2022 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer |
|
| December 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2021 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employe |
|
| November 22, 2021 |
Exhibit 99.1 Neurocrine Biosciences and Sosei Heptares Announce Collaboration to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders Neurocrine Biosciences anticipates initiating a Phase 2 study with the selective M4 agonist HTL-0016878 in schizophrenia in 2022 and Phase 1 studies for a dual M1/M4 and selective M1 agonist in 2023 Sosei Heptares receive |
|
| November 22, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2021 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employe |
|
| November 3, 2021 |
November 3, 2021 Via EDGAR and FedEx Ms. Jeanne Baker Mr. Terence O'Brien United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Re: Neurocrine Biosciences, Inc. Form 10-K filed February 5, 2021 Form 8-K filed August 3, 2021 Form 8-K filed February 4, 2021 File No. 000-22705 Ladies and Gentlemen: This letter is |
|
| November 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-22705 NEUROCRI |
|
| November 1, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2021 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer |
|
| November 1, 2021 |
Neurocrine Biosciences Reports Third Quarter 2021 Financial Results Exhibit 99.1 Neurocrine Biosciences Reports Third Quarter 2021 Financial Results INGREZZA? (valbenazine) Third Quarter 2021 Net Product Sales of $287 Million with Approximately 52,000 Total Prescriptions SAN DIEGO, Nov. 1, 2021 - Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2021. ?Our third quarter results reflect INGRE |
|
| October 5, 2021 |
October 5, 2021 Via EDGAR and FedEx Ms. Jeanne Baker Mr. Terence O'Brien United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Re: Neurocrine Biosciences, Inc. Form 10-K for the fiscal year ended December 31, 2020, filed February 5, 2021 Form 8-K filed August 3, 2021 Form 8-K filed February 4, 2021 File No. 00 |
|
| August 3, 2021 |
Neurocrine Biosciences Reports Second Quarter 2021 Financial Results Exhibit 99.1 Neurocrine Biosciences Reports Second Quarter 2021 Financial Results INGREZZA? (valbenazine) Second Quarter 2021 Net Product Sales of $265 Million with Approximately 48,900 Total Prescriptions Phase 3 Registrational Program of Valbenazine for the Treatment of Chorea Associated with Huntington Disease Fully Enrolled with Top-Line Data Expected by Year-End SAN DIEGO, August 3, 2021 - Ne |
|
| August 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-22705 NEUROCRINE BI |
|
| August 3, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2021 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer o |
|
| May 21, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2021 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer of |
|
| May 5, 2021 |
Neurocrine Biosciences Reports First Quarter 2021 Financial Results Exhibit 99.1 Neurocrine Biosciences Reports First Quarter 2021 Financial Results INGREZZA? (valbenazine) First Quarter 2021 Net Product Sales of $230 Million with Approximately 43,300 TRx Initiated Pediatric Phase III Registrational Program of Crinecerfont for the Treatment of Classic Congenital Adrenal Hyperplasia Initiated Phase II Study of NBI-827104 in Essential Tremor SAN DIEGO, May 5, 2021 - |
|
| May 5, 2021 |
Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT NEUROCRINE BIOSCIENCES, INC. TREATS AS PRIVATE OR CONFIDENTIAL. First Amendment (?First Amendment?) to the Collaboration And License Agreement dated as of June 15, 2010 (the ?Collaboration Agreement?) by and between Abbott Interna |
|
| May 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-22705 NEUROCRINE B |
|
| May 5, 2021 |
Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT NEUROCRINE BIOSCIENCES, INC. TREATS AS PRIVATE OR CONFIDENTIAL. COLLABORATION AND LICENSE AGREEMENT THIS COLLABORATION AND LICENSE AGREEMENT (the ?Agreement?) is entered into as of March 31, 2015 (the ? Effective Date ?), by and be |
|
| May 5, 2021 |
License Agreement dated February 9, 2017 between BIAL- Portela & CA, S.A. and the Company Exhibit 10.4 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT NEUROCRINE BIOSCIENCES, INC. TREATS AS PRIVATE OR CONFIDENTIAL. LICENSE AGREEMENT THIS LICENSE AGREEMENT (this ?Agreement?) is made and entered into as of February 9, 2017 (the ? Effective Date ?) by and between BIAL ? PORTELA & C |
|
| May 5, 2021 |
Exhibit 3.2 BYLAWS OF NEUROCRINE BIOSCIENCES, INC. (a Delaware corporation) BYLAWS OF NEUROCRINE BIOSCIENCES, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I-CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II-MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 NOTICE OF STOCKHOLDERS? MEETINGS 2 2.5 ADVANCE NOTICE |
|
| May 5, 2021 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT NEUROCRINE BIOSCIENCES, INC. TREATS AS PRIVATE OR CONFIDENTIAL COLLABORATION AGREEMENT dated June 15, 2010 by and between Abbott International Luxembourg S.? r.l. and Neurocrine Biosciences, Inc. CONFIDENTIAL EXHIBIT INDEX A ? Ela |
|
| May 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2021 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer of I |
|
| April 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2021 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer o |
|
| April 16, 2021 |
Certificate of Amendment of Bylaws Exhibit 3.1 BYLAW AMENDMENT 3.2 NUMBER OF DIRECTORS The board of directors shall consist of nine (9) members. The number of directors may be changed by an amendment to this bylaw, duly adopted by the board of directors or by the stockholders, or by a duly adopted amendment to the certificate of incorporation. The directors shall be divided into three classes, with the term of office of the first c |
|
| April 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Neurocrine Biosciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 64125C109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Neurocrine Biosciences Inc. Title of Class of Securities: Common Stock CUSIP Number: 64125C109 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-22705 NEUROCRINE BIOSCIENCES, INC. (E |
|
| February 5, 2021 |
Exhibit 21.1 NEUROCRINE BIOSCIENCES INC. SUBSIDIARIES Name of Subsidiary Jurisdiction Neurocrine Continental, Inc. Delaware, USA Neurocrine Europe, Ltd. Ireland Neurocrine Therapeutics, Ltd. Ireland |
|
| February 4, 2021 |
Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results Exhibit 99.1 Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results Total Annual Revenues in 2020 Grew 33% to Over $1 Billion INGREZZA® (valbenazine) Full Year 2020 Net Product Sales and TRx Both Grew 32% to $993 Million and Approximately 175,700 TRx, Respectively Mitsubishi Tanabe Pharma Corporation (MTPC) Reports Successful Top-Line Results for Asia-Based J-KINECT Pha |
|
| February 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2021 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer |
|
| February 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2021 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer |
|
| January 8, 2021 |
Exhibit 99.1 Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2020 Net Product Sales Results and 2021 Program Milestones INGREZZA® (valbenazine) Preliminary Fourth Quarter Net Product Sales and Inventory Adjusted Net Product Sales of Approximately $240 Million and $258 Million, Respectively INGREZZA® (valbenazine) Preliminary Full-Year 2020 Net Product Sales and TRx Both Gr |
|
| January 8, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2021 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer |
|
| November 24, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 23, 2020 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employe |
|
| November 19, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2020 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employe |
|
| November 19, 2020 |
Neurocrine Biosciences Announces Repurchase of Convertible Notes Exhibit 99.1 Neurocrine Biosciences Announces Repurchase of Convertible Notes SAN DIEGO, Nov. 19, 2020 - Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the Company has entered into separate, privately negotiated transactions (the “Agreements”) with certain holders of its existing 2.25% Convertible Senior Notes due 2024 (the “2024 Notes”) to repurchase approximately $83 million ag |
|
| November 9, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2020 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer |
|
| November 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-22705 NEUROCRI |
|
| November 9, 2020 |
Neurocrine Biosciences Reports Third Quarter 2020 Financial Results Exhibit 99.1 Neurocrine Biosciences Reports Third Quarter 2020 Financial Results INGREZZA® (valbenazine) Third Quarter Net Product Sales of $254 million with Approximately 45,100 TRx ONGENTYS® (opicapone) Now Available in the U.S. as an Add-On Treatment for Patients with Parkinson’s Disease Experiencing “Off” Episodes Initiating Phase II Study of NBI-827104, a Clinical Stage Selective T-type Calci |
|
| September 10, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2020 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employe |
|
| September 10, 2020 |
Neurocrine Biosciences at Citi 15 Exhibit 99.1 Neurocrine Biosciences at Citi 15th Annual Biopharma Virtual Conference September 09, 2020 @ 12:35PM ET Corporate Participant Kevin C. Gorman Neurocrine Biosciences, Inc. – CEO & Director Conference Call Participant Neena Bitritto-Garg Citi Investment Research - VP Presentation Neena Bitritto-Garg Citi Investment Research – VP So hi everyone. Thank you so much for joining the 15th Ann |
|
| August 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2020 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer |
|
| August 28, 2020 |
Certificate of Amendment of Bylaws Exhibit 3.1 CERTIFICATE OF AMENDMENT OF BYLAWS OF NEUROCRINE BIOSCIENCES, INC. (A DELAWARE CORPORATION) On August 28, 2020, the Board of Directors of Neurocrine Biosciences, Inc. approved the amendment of Article X of the Bylaws of the corporation to read as follows: ARTICLE X FORUM FOR ADJUDICATION OF DISPUTES 10.1. Unless the corporation consents in writing to the selection of an alternative for |
|
| August 3, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2020 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer o |
|
| August 3, 2020 |
As filed with the Securities and Exchange Commission on August 3, 2020 Registration No. |
|
| August 3, 2020 |
Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan Exhibit 10.1 Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan Adopted by the Compensation Committee: March 16, 2020 Approved by the Stockholders: May 19, 2020 Termination Date: March 15, 2030 Table of Contents Page General. 1 Shares Subject to the Plan. 1 Eligibility and Limitations. 2 Options and Stock Appreciation Rights. 4 Awards Other Than Options and Stock Appreciation Rights. 7 Adjust |
|
| August 3, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-22705 NEUROCRINE BI |
|
| August 3, 2020 |
Neurocrine Biosciences Reports Second Quarter 2020 Financial Results Exhibit 99.1 Neurocrine Biosciences Reports Second Quarter 2020 Financial Results INGREZZA® (valbenazine) Second Quarter Net Product Sales of $268 million with Approximately 46,400 TRx Two Medicines Approved by the U.S. Food and Drug Administration (FDA) During the Second Quarter, ONGENTYS® (opicapone) for Parkinson’s Disease and ORIAHNNTM (elagolix, estradiol, and norethindrone acetate capsules; |
|
| August 3, 2020 |
Exhibit 10.2 Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan Option Grant Notice Neurocrine Biosciences, Inc. (the “Company”) has granted to you (“Participant”) an option to purchase the number of shares of Common Stock set forth below (the “Option”) under the Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan (the “Plan”). The Option is subject to all of the terms and conditions set |
|
| August 3, 2020 |
As filed with the Securities and Exchange Commission on August 3, 2020 Registration No. |
|
| August 3, 2020 |
Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. CONFIDENTIAL Execution Version Exclusive License Agreement by and Between Takeda Pharmaceutical Company Limited and Neurocrine Biosciences, Inc. June 12, 2020 TABLE OF CONTENTS 1. DEFINIT |
|
| July 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHING7TON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2020 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer o |
|
| July 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2020 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| June 16, 2020 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2020 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| June 16, 2020 |
Exhibit 99.1 Neurocrine Biosciences and Takeda Announce Collaboration to Develop and Commercialize Potential Therapies for Psychiatric Disorders − Strategic partnership agreement provides Neurocrine Biosciences exclusive worldwide rights to early-to-mid-stage psychiatry pipeline compounds within Takeda’s Neuroscience portfolio − Collaboration includes three clinical-stage assets with the most adva |
|
| May 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2020 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-22705 NEUROCRINE B |
|
| May 6, 2020 |
Neurocrine Biosciences Reports First Quarter 2020 Financial Results Exhibit 99.1 Neurocrine Biosciences Reports First Quarter 2020 Financial Results INGREZZA® (valbenazine) First Quarter Net Product Sales of $231 Million with Approximately 41,500 TRx ONGENTYS® (opicapone) Approved by the U.S. Food and Drug Administration (FDA) as a Once-Daily Adjunctive Treatment for Patients with Parkinson’s Disease Experiencing “Off” Episodes Results of the Phase II Proof-of-Con |
|
| May 6, 2020 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2020 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 9, 2020 |
NBIX / Neurocrine Biosciences, Inc. DEFA14A - - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2020 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| February 14, 2020 |
EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2020 PERCEPTIVE ADVISORS LLC |
|
| February 14, 2020 |
NBIX / Neurocrine Biosciences, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Neurocrine Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 64125C 10 9 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| February 12, 2020 |
NBIX / Neurocrine Biosciences, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Neurocrine Biosciences Inc Title of Class of Securities: Common Stock CUSIP Number: 64125C109 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is f |
|
| February 7, 2020 |
EXHIBIT 21.1 NEUROCRINE BIOSCIENCES INC. SUBSIDIARIES NAME OF SUBSIDIARY JURISDICTION Neurocrine Continental, Inc. Delaware, USA Neurocrine Europe, Ltd. Ireland Neurocrine Therapeutics, Ltd. Ireland |
|
| February 7, 2020 |
Description of Common Stock of the Registrant Exhibit 4.4 DESCRIPTION OF COMMON STOCK The following summary description of the common stock of Neurocrine Biosciences, Inc., or we, our or us is based on the provisions of our certificate of incorporation, as amended, as well as our bylaws, as amended, and the applicable provisions of the Delaware General Corporation Law. This information is qualified entirely by reference to the applicable prov |
|
| February 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-22705 NEUROCRINE BIOSCIENCES, INC. (E |
|
| February 7, 2020 |
Employment Agreement dated November 3, 2014 between the Company and Kyle Gano Exhibit 10.16 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT is effective as of the last date signed by the parties hereto (the “Effective Date”) and is entered into by and between NEUROCRINE BIOSCIENCES, INC., 12780 El Camino Real, San Diego, California 92130 (hereinafter the “Company”), and Kyle Gano (hereinafter “Executive”). R E C IT A L S WHEREAS, the Company and Executive wish to set forth i |
|
| February 5, 2020 |
Exhibit 99.1 THOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT NBIX - Q4 2019 Neurocrine Biosciences Inc Earnings Call EVENT DATE/TIME: FEBRUARY 04, 2020 / 9:30PM GMT FEBRUARY 04, 2020 / 9:30PM, NBIX - Q4 2019 Neurocrine Biosciences Inc Earnings Call CORPORATE PARTICIPANTS Eiry Wyn Roberts Neurocrine Biosciences, Inc. - Chief Medical Officer Eric S. Benevich Neurocrine Biosciences, Inc. - Chief Comme |
|
| February 5, 2020 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2020 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 4, 2020 |
Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2019 Financial Results Exhibit 99.1 Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2019 Financial Results INGREZZA® (valbenazine) Fourth Quarter Net Product Sales of $238 Million with Approximately 42,100 TRx INGREZZA® (valbenazine) Full-Year 2019 Net Product Sales of $753 Million with Approximately 132,700 TRx SAN DIEGO, Feb. 4, 2020 - Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financi |
|
| February 4, 2020 |
Certificate of Amendment of Bylaws Exhibit 3.1 BYLAW AMENDMENT 3.2 NUMBER OF DIRECTORS The board of directors shall consist of nine (9) members. The number of directors may be changed by an amendment to this bylaw, duly adopted by the board of directors or by the stockholders, or by a duly adopted amendment to the certificate of incorporation. The directors shall be divided into three classes, with the term of office of the first c |
|
| February 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2020 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction of Incorporation) (Commis |
|
| January 13, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2020 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction of Incorporation) (Commis |
|
| January 13, 2020 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2019 Net Product Sales Results and 2020 Program Milestones - INGREZZA® (valbenazine) Preliminary Fourth Quarter Net Product Sales of Approximately $238 Million with Approximately 42,100 TRx - INGREZZA® (valbenazine) Preliminary Full-Year 2019 Net Product Sales of Approximately $753 Million w |
|
| December 11, 2019 |
XENE / Xenon Pharmaceuticals Inc. / Neurocrine Biosciences Inc - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* XENON PHARMACEUTICALS INC. (Name of Issuer) Common Stock, without par value (Title of Class of Securities) 98420N105 (CUSIP Number) Kevin C. Gorman, Ph.D. Chief Executive Officer Neurocrine Biosciences, Inc. 12780 El Camino Real San Diego, CA 92130 (858) |
|
| November 5, 2019 |
NBIX / Neurocrine Biosciences, Inc. S-8 - - S-8 As filed with the Securities and Exchange Commission on November 4, 2019 Registration No. |
|
| November 4, 2019 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2019 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 4, 2019 |
Neurocrine Biosciences Reports Third Quarter 2019 Financial Results Exhibit 99.1 Neurocrine Biosciences Reports Third Quarter 2019 Financial Results INGREZZA® (valbenazine) Third Quarter Net Product Sales of $198.1 Million with Approximately 34,800 TRx Initiated KINECT-HD Phase III Study of Valbenazine to Treat Chorea in Patients with Huntington’s Disease SAN DIEGO, Nov. 4, 2019 - Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results fo |
|
| November 4, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-22705 NEUROCRI |
|
| November 4, 2019 |
Exhibit 10.1 THIRD AMENDMENT TO AMENDED AND RESTATED LEASE This THIRD AMENDMENT TO AMENDED AND RESTATED LEASE ("Third Amendment") is made and entered into as of August 7, 2019, by and between KILROY REALTY, L.P., a Delaware limited partnership ("Landlord"), and NEUROCRINE BIOSCIENCES, INC., a Delaware corporation ("Tenant"). r e c i t a l s : A. Landlord (as successor-in-interest to DMH CAMPUS INV |
|
| September 11, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2019 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction of Incorporation) (Comm |
|
| July 29, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 nbix-8k20190729.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2019 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdictio |
